High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine the effects of escalated dose of daunorubicin in induction treatment of adult patients with acute myelogenous leukemia who are younger than 60 years of age.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cooperative Study Group A for Hematology
• Treatments: Daunorubicin

Criteria

Inclusion Criteria:

• Patients with newly diagnosed AML or RAEB

• 15 years of age or older, but younger than 60 years of age

• Adequate hepatic and renal function

• Normal cardiac function with LVEF ≥ 50% on MUGA scan or echocardiogram

• Written informed consent

Exclusion Criteria:

• promyelocytic leukemia or chronic myelogenous leukemia

• significant infection

• prior chemotherapy history for leukemia